My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1005

    1.

    The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

    Diabetes Atorvastin Lipid Intervention (DALI) Study Group.

    Diabetes Care. 2001 Aug;24(8):1335-41.PMID: 11473066 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.

    Pontrelli L, Parris W, Adeli K, Cheung RC.

    Metabolism. 2002 Mar;51(3):334-42.PMID: 11887170 [PubMed - indexed for MEDLINE]Related articles

    3.

    Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

    Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

    Clin Ther. 2008 Dec;30(12):2298-313.PMID: 19167589 [PubMed - indexed for MEDLINE]Related articles

    4.

    A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

    Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O; 3T Study Investigators.

    Clin Ther. 2003 Jan;25(1):119-38.PMID: 12637115 [PubMed - indexed for MEDLINE]Related articles

    5.

    A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

    Harris KP, Wheeler DC, Chong CC; Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis.

    Kidney Int. 2002 Apr;61(4):1469-74.PMID: 11918754 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H; Diabetes Atorvastatin Lipid intervention (DALI) Study Group.

    Diabetes Care. 2004 Jun;27(6):1358-64.PMID: 15161788 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

    Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM.

    JAMA. 1996 Jan 10;275(2):128-33.PMID: 8531308 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

    Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ.

    Am J Cardiol. 2002 Oct 1;90(7):689-96.PMID: 12356379 [PubMed - indexed for MEDLINE]Related articles

    9.

    Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.

    Castaño G, Mas R, Fernández L, Illnait J, Mesa M, Alvarez E, Lezcay M.

    Drugs Aging. 2003;20(2):153-63.PMID: 12534315 [PubMed - indexed for MEDLINE]Related articles

    10.

    Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.

    van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD; DALI Study Group.

    Diabetes Care. 2002 Jul;25(7):1211-6.PMID: 12087021 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

    Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R.

    Am J Cardiol. 2002 Mar 15;89(6):667-71.PMID: 11897207 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.

    Schrott HG, Knapp H, Davila M, Shurzinske L, Black D.

    Am Heart J. 2000 Aug;140(2):249-52.PMID: 10925339 [PubMed - indexed for MEDLINE]Related articles

    13.

    Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

    Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB.

    Clin Ther. 2003 Jun;25(6):1670-86.PMID: 12860491 [PubMed - indexed for MEDLINE]Related articles

    14.

    Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.

    Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H.

    Am J Cardiol. 2002 Feb 1;89(3):268-75.PMID: 11809427 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.

    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.

    Am J Cardiol. 2001 Jan 1;87(1):44-8.PMID: 11137832 [PubMed - indexed for MEDLINE]Related articles

    16.

    A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.

    Clin Ther. 2008 Jun;30(6):1089-101.PMID: 18640465 [PubMed - indexed for MEDLINE]Related articles

    17.

    Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

    Am Heart J. 2004 Sep;148(3):447-55.PMID: 15389231 [PubMed - indexed for MEDLINE]Related articles

    18.

    Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.

    Diabetes Care. 2002 Jul;25(7):1198-202.PMID: 12087019 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.

    van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.

    Curr Med Res Opin. 2009 Jan;25(1):93-101.PMID: 19210142 [PubMed - indexed for MEDLINE]Related articles

    20.

    Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.

    Velussi M.

    Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):29-35.PMID: 12125227 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity